Summary

The Vaccine Manufacturing Market is expected to reach USD 2.38 billion by 2024 anticipated to grow at a CAGR of 6.5% during the forecast period 2024-2035.

The vaccine industry is experiencing a surge in demand, driven by the rapid development of new vaccines targeting various infectious diseases, oncological and autoimmune disorders. As the pipeline of vaccines grows, pharmaceutical companies are turning to contract manufacturers to provide large-scale production services for complex vaccines like mRNA and viral vectors. Vaccines play a vital role in preventing serious illnesses, and recent advancements in vaccine technology have marked significant milestones.
The approval of numerous FDA-approved vaccines, including the first vaccine for respiratory syncytial virus (RSV) and chikungunya, signals a paradigm shift in the vaccine industry. This growth has led to an explosion of opportunities for contract manufacturing organizations (CMOs) specializing in vaccines, with over 130 vaccine CMOs established since 2000. To stay competitive, CMOs are investing in cutting-edge technology and expanding their capacities to meet the escalating demand for vaccines.
Outsourcing is becoming increasingly accepted as a viable and beneficial business model in the vaccine industry, driving the growth of the global vaccine contract manufacturing market. This trend is also boosting the success of vaccine adjuvants companies, which are developing innovative adjuvants for vaccine developers and manufacturers. As the demand for vaccines continues to grow, contract manufacturers are poised to play a critical role in meeting this demand, driving innovation and improving public health outcomes.


Research Coverage:
 A comprehensive overview providing an in-depth look at vaccine contract manufacturing, highlighting the various expression systems used in the development and production of vaccines. Additionally, it provides a concise explanation of the fundamental principles and benefits of contract manufacturing, underscoring its growing significance in the vaccine industry.
 Detailed analysis of the contract manufacturing landscape of companies offering contract services based on several parameters, such as their year of establishment, company size, and location of headquarters. Additionally, this overview covers the types of services offered by these companies, including analytical testing, cell line development and virus banking, fill and finish, formulation development, process development, and regulatory consulting. The scale of operation is also examined, encompassing preclinical, clinical, and commercial stages. Furthermore, the overview explores the expression systems employed by these companies, including avian, insect, mammalian, microbial, and others. The review also delves into the types of vaccines manufactured by these companies, including live attenuated vaccines, inactivated vaccines, DNA vaccines, RNA-based vaccines (such as COVID-19 vaccines), subunit vaccines, toxoid-based vaccines, and others.
 Detailed analysis of the competitiveness of leading players in the contract vaccine manufacturing industry, focusing on a multi-faceted evaluation of their company strengths. This assessment considers factors, such as the experience and reputation of the contract manufacturer, as well as their portfolio strength, which encompasses various elements including the scale of their operation, the range of vaccines they manufacture, the types of services they offer, their manufacturing capabilities, and the number of facilities they operate.
 Detailed company profiles of the key service providers in the vaccine contract manufacturing market, based in North America. Each profile features a brief overview of the vaccine contract manufacturing service provider, along with information on location of headquarters, year of establishment, number of employees, leadership team, service portfolio, recent developments, and an informed future outlook.
 Comprehensive profiles of leading vaccine contract manufacturing service providers based in Europe are presented, providing a comprehensive overview of each company's strengths and capabilities. Each profile includes essential information such as the company's headquarters location, year of establishment, employee count, leadership team, service offerings, recent developments, and an expert forecast of future prospects. This detailed analysis enables a deeper understanding of the key players in the vaccine CMO market, their competitive positions, and their potential for growth and innovation.
 Detailed profiles of the leading service providers in the vaccine contract manufacturing market, based in Asia-Pacific. Each profile features a brief overview of the vaccine contract manufacturing service provider, along with information on location of headquarters, year of establishment, number of employees, leadership team, service portfolio, recent developments, and an informed future outlook.
 An in-depth examination of partnerships signed between industry stakeholders in the vaccine contract manufacturing sector, based on a range of criteria. This analysis delves into the details of partnerships signed between since 2019, including the year of partnership, partnership type, therapeutic area, type of vaccine manufactured, and type of partner. Additionally, the report highlights the most active players in the industry, as measured by the number of partnerships they have signed during this period. The regional distribution of partnership activity is also mapped, providing a comprehensive understanding of the trends and dynamics driving collaboration in the vaccine contract manufacturing industry.
 Detailed analysis of the expansion initiatives undertaken by vaccine contract manufacturers since 2020 is presented, analyzing various factors that influenced these developments. This analysis dissects the expansion initiatives based on key parameters, including the year of expansion, purpose of expansion (capacity expansion, capability expansion, new facility, geographical consolidation, and geographical expansion), location of the expanded facility, and investment amount. The report also identifies the most active players in the industry, measured by the number of expansion initiatives they have undertaken during this period. This in-depth analysis provides a detailed understanding of the strategic moves made by vaccine contract manufacturers to enhance their capabilities and expand their presence in the market.
 This report provides an in-depth analysis of the mergers and acquisitions that have occurred in the vaccine contract manufacturing industry since 2018, examining various factors that influenced these deals. The analysis delves into the details of each transaction, considering key parameters such as the year of agreement, deal type, geographical location, acquisition type, biologic type, therapeutic area, and key value drivers. The report provides a comprehensive understanding of the strategic decisions made by companies in the industry to expand their capabilities, gain market share, and enhance their competitiveness. By examining these deals, this analysis aims to identify trends and patterns in the industry's M&A landscape, providing insights into the evolution of the industry over time.
 This report presents a comprehensive assessment of the global vaccine manufacturing capacity, utilizing publicly available data from industry stakeholders. The analysis highlights the distribution of available vaccine production capacity across various parameters, including company size, expression system, and geographical region. The report provides a snapshot of the industry's current capacity landscape, offering valuable insights into the market share and competitive positioning of various vaccine manufacturers. By examining the distribution of capacity across different company sizes, expression systems, and regions, this report aims to uncover the trends and patterns that shape the vaccine manufacturing industry, providing a deeper understanding of its current state and future direction.
 An informed assessment of the projected annual demand for vaccines, based on commercial and clinical needs, across key geographical regions.
 An in-depth framework for evaluating vaccine manufacturing CMO vendors, identifying key factors to consider when outsourcing operations, and providing a structured approach for stakeholders to assess potential vendors and make informed decisions about their outsourcing needs.
 Detailed analysis capturing the key parameters and trends that are likely to influence the future of vaccine contract manufacturing, under a SWOT framework.
 A thorough examination of the vaccine contract manufacturing market, identifying and analyzing the critical factors that influence its growth trajectory. This includes a detailed assessment of key drivers, such as trends and market forces, as well as potential restraints, emerging opportunities, and existing challenges that can impact the market's development and expansion.
 An exhaustive analysis of the vaccine contract manufacturing market, providing a comprehensive estimate of the current market size and its potential growth over the next decade. Our forecast is based on a thorough examination of adoption trends and validated through both secondary and primary research. The report includes an in-depth assessment of the market's evolution from 2025 to 2035, including the distribution of current and forecasted opportunities across the vaccine contract manufacturing industry. To ensure accuracy and resilience, we have also developed three market forecast scenarios, representing conservative, base, and optimistic growth trajectories, to account for future uncertainties and potential market developments.
 Extensive forecasts of the current and future market opportunities for service providers in the vaccine contract manufacturing market, segmented by expression system type, including mammalian, microbial, and other systems. This analysis provides a detailed breakdown of the potential for growth and development across each category, enabling stakeholders to make informed decisions about their market strategies.
 Detailed projections of the current and future opportunity for service providers in the vaccine contract manufacturing market across company size, namely small, mid-sized and large / very large.
 Comprehensive predictions of the current and future opportunity for service providers in the vaccine CMO market across different key geographical regions, namely North America, Europe, Asia-Pacific and rest of the world.
Key Benefits of Buying this Report
 The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
 Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
 The report provides stakeholders with a pulse on the Vaccine Contract Manufacturing Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies
 AGC Biologics
 Bharat Biotech
 Biological E
 BioReliance
 Boehringer Ingelheim BioXcellence
 Catalent
 Charles River Laboratories
 Cobra Biologics
 Curia
 Eurofins Amatsigroup
 Eurogentec
 GreenPak Biotech
 Hong Kong Institute of Biotechnology
 IDT Biologika
 Lonza
 Meridian Life Sciences
 Syngene International
 WuXi Biologics
 Wockhardt

ページTOPに戻る

Table of Contents

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databased and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
4.1. Chapter Overview
5. INTRODUCTION
5.1. Chapter Overview
5.2. Classification of Vaccines based on Type of Active Ingredient
5.2.1. Live, Attenuated Vaccines
5.2.2. Inactivated Vaccines
5.2.3. Subunit Vaccines
5.2.4. Toxoid Vaccines
5.2.5. DNA Vaccines
5.3. Key Components of Vaccine Formulations
5.4. Vaccine Development and Manufacturing
5.4.1. Identification of Antigen and Manufacturing Process Development
5.4.2. Production of Vaccines in Different Expression Systems
5.4.2.1. Avian Expression Systems
5.4.2.2. Bacterial Expression Systems
5.4.2.3. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
5.4.2.4. Insect Expression Systems
5.4.2.5. Mammalian Expression Systems
5.4.2.6. Plant Expression Systems
5.4.2.7. Yeast Expression Systems
5.4.3. Vaccine Manufacturing Process
5.4.3.1. Upstream Process
5.4.3.2. Downstream Process
5.4.3.3. Formulation and Fill / Finish
5.4.4. Clinical Development and Approval
5.4.5. Vaccine Supply Chain and Logistics
5.5. Vaccine Contract Manufacturing
5.5.1. Need for Outsourcing Vaccine Manufacturing Operations
5.5.2. Commonly Outsourced Operations
5.5.3. Selecting a Contract Manufacturing Partner
5.5.4. Advantages of Outsourcing Manufacturing Operations
5.5.5. Risks and Challenges Associated with Contract Manufacturing
5.6. Future Perspectives
6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Vaccine Contract Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Type of Service Offered
6.2.5. Analysis by Scale of Operation
6.2.6. Analysis by Type of Expression System Used
6.2.7. Analysis by Type of Vaccine Manufactured
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions And Key Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis: Vaccine Contract Manufacturers in North America
7.5. Company Competitiveness Analysis: Vaccine Contract Manufacturers in Europe
7.6. Company Competitiveness Analysis: Vaccine Contract Manufacturers in Asia-Pacific
7.7. Company Competitiveness Analysis: Vaccine Contract Manufacturers in Rest of the World
8. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS IN NORTH AMERICA
8.1. Chapter Overview
8.2. AGC Biologics
8.2.1. Company Overview
8.2.2. Recent Developments and Future Outlook
8.3. Bioreliance
8.3.1. Company Overview
8.3.2. Recent Developments and Future Outlook
8.4. Catalent
8.4.1. Company Overview
8.4.2. Recent Developments and Future Outlook
8.5. Charles River Laboratories
8.5.1. Company Overview
8.5.2. Recent Developments and Future Outlook
8.6. Curia
8.6.1. Company Overview
8.6.2. Recent Developments and Future Outlook
8.7. Meridian Life Science
8.7.1. Company Overview
8.7.2. Recent Developments and Future Outlook
9. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS IN EUROPE
9.1. Chapter Overview
9.2. Boehringer Ingelheim BioXcellence
9.2.1. Company Overview
9.2.2. Recent Developments and Future Outlook
9.3. Eurofins Amatsigroup
9.3.1. Company Overview
9.3.2. Recent Developments and Future Outlook
9.4. Eurogentec
9.4.1. Company Overview
9.4.2. Recent Developments and Future Outlook
9.5. IDT Biologika
9.5.1. Company Overview
9.5.2. Recent Developments and Future Outlook
9.6. Lonza
9.6.1. Company Overview
9.6.2. Recent Developments and Future Outlook
10. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS IN ASIA-PACIFIC
10.1. Chapter Overview
10.2. Bharat Biotech
10.2.1. Company Overview
10.2.2. Recent Developments and Future Outlook
10.3. Biological E
10.3.1. Company Overview
10.3.2. Recent Developments and Future Outlook
10.4. GreenPak Biotech
10.4.1. Company Overview
10.4.2. Recent Developments and Future Outlook
10.5. Hong Kong Institute of Biotechnology
10.5.1. Company Overview
10.5.2. Recent Developments and Future Outlook
10.6. Syngene International
10.6.1. Company Overview
10.6.2. Recent Developments and Future Outlook
10.7. Wockhardt
10.7.1. Company Overview
10.7.2. Recent Developments and Future Outlook
10.8. WuXi Biologics
10.8.1. Company Overview
10.8.2. Recent Developments and Future Outlook
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Model
11.3. Vaccine Contract Manufacturers: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Therapeutic Area
11.3.5. Most Active Players: Analysis by Number of Partnerships
11.3.6. Analysis by Geography
11.3.6.1. Intracontinental and Intercontinental Agreements
11.3.6.2. International and Local Deals
12. RECENT EXPANSIONS
12.1. Chapter Overview
12.2. Vaccine Contract Manufacturers: Recent Expansions
12.2.1. Analysis by Year of Expansion
12.2.2. Analysis by Purpose of Expansion
12.2.3. Analysis by Year and Purpose of Expansion
12.2.4. Analysis by Location of Expanded Facility
12.2.5. Analysis by Purpose of Expansion and Location of Expanded Facility
12.2.6. Analysis by Amount Invested
12.2.7. Most Active Players: Analysis by Number of Recent Expansions
13. MERGERS AND ACQUSITIONS
13.1. Chapter Overview
13.2. Merger and Acquisition Models
13.3. Vaccine Contract Manufacturing: Mergers and Acquisitions
13.3.1. Analysis by Year of Agreement
13.3.2. Analysis by Type of Agreement
13.3.3. Analysis by Geography
13.3.3.1. Intercontinental and Intracontinental Agreements
13.3.3.2. Local and International Agreements
13.3.4. Year-wise Trend in Key Geographies
13.3.5. Most Active Players: Analysis by Number of Agreements
13.4. Concluding Remarks
14. CAPACITY ANALYSIS
14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Vaccine Contract Manufacturing: Global Installed Capacity
14.3.1. Analysis by Company Size
14.3.2. Analysis by Type of Expression System Used
14.3.3. Analysis by Location of Manufacturing Facility
14.4. Concluding Remarks
15. DEMAND ANALYSIS
15.1. Chapter Overview
15.2. Assumptions and Methodology
15.3. Global Demand for Vaccines
15.3.1. Global Clinical Demand for Vaccines
15.3.2. Global Commercial Demand for Vaccines
15.4. Analysis by Geography
15.5. Global Clinical Demand for COVID-19 Vaccines
15.6. Global Commercial Demand for COVID-19 Vaccines
16. VENDOR SELECTION FRAMEWORK ANALYSIS
16.1. Chapter Overview
16.2. Reasons to Outsource in Vaccine Manufacturing
16.3. Commonly Outsourced Operations in Vaccine Manufacturing
16.4. Key Parameters
16.5. Methodology
16.6. Comparison of Parameters
16.7. Value Addition vs Evaluation Complexity Matrix
16.8. Case Study Assessment of Leading Players
16.9. Overview of Vendor Assessment Dashboard
16.9.1. Scenario I
16.9.2. Scenario II
16.9.3. Scenario III
16.10. Concluding Remarks

17. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Vaccine Contract Manufacturing Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.1. Scenario Analysis
17.3.1.1. Conservative Scenario
17.3.1.2. Optimistic Scenario
17.4. Key Market Segmentation
17.5. Global COVID-19 Contract Manufacturing Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Vaccine Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, 2024 and 2035
18.3.1. Vaccine Contract Manufacturing Market for Mammalian Expression Systems: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
18.3.2. Vaccine Contract Manufacturing Market for Microbial Expression Systems: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
18.3.3. Vaccine Contract Manufacturing Market for Other Expression Systems: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
18.4. Data Triangulation and Validation
19. VACCINE CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Vaccine Contract Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
19.3.1. Vaccine Contract Manufacturing Market for Small Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.3.2. Vaccine Contract Manufacturing Market for Mid-sized Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.3.3. Vaccine Contract Manufacturing Market for Large and Very Large Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.4. Data Triangulation and Validation
20. VACCINE CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Vaccine Contract Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
20.3.1. Vaccine Contract Manufacturing Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.1.1. Vaccine Contract Manufacturing Market in US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.1.2. Vaccine Contract Manufacturing Market in Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.1.3. Vaccine Contract Manufacturing Market in Rest of North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.1.4. Vaccine Contract Manufacturing Market for Mammalian Expression System in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.1.5. Vaccine Contract Manufacturing Market for Microbial Expression System in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.1.6. Vaccine Contract Manufacturing Market for Other Expression System t in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.1.7. Vaccine Contract Manufacturing Market for Small Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.1.8. Vaccine Contract Manufacturing Market for Mid-sized Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.1.9. Vaccine Contract Manufacturing Market for Large / Very Large Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.2. Vaccine Contract Manufacturing Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.2.1. Vaccine Contract Manufacturing Market in Germany: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.2.2. Vaccine Contract Manufacturing Market in UK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.2.3. Vaccine Contract Manufacturing Market in France: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.2.4. Vaccine Contract Manufacturing Market in Italy: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.2.5. Vaccine Contract Manufacturing Market in Spain: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.2.6. Vaccine Contract Manufacturing Market in Rest of Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.2.7. Vaccine Contract Manufacturing Market for Mammalian Expression System in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.2.8. Vaccine Contract Manufacturing Market for Microbial Expression System in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.2.9. Vaccine Contract Manufacturing Market for Other Expression System in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.2.10. Vaccine Contract Manufacturing Market for Small Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.2.11. Vaccine Contract Manufacturing Market for Mid-sized Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.2.12. Vaccine Contract Manufacturing Market for Large / Very Large Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.3. Vaccine Contract Manufacturing Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.3.1. Vaccine Contract Manufacturing Market in China: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.3.2. Vaccine Contract Manufacturing Market in India: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.3.3. Vaccine Contract Manufacturing Market in Japan: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.3.4. Vaccine Contract Manufacturing Market in Rest of Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.3.5. Vaccine Contract Manufacturing Market for Mammalian Expression System in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.3.6. Vaccine Contract Manufacturing Market for Microbial Expression System in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.3.7. Vaccine Contract Manufacturing Market for Other Expression System in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.3.8. Vaccine Contract Manufacturing Market for Small Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.3.9. Vaccine Contract Manufacturing Market for Mid-sized Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.3.10. Vaccine Contract Manufacturing Market for Large / Very Large Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.3.4. Vaccine Contract Manufacturing Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
20.4. Data Triangulation and Validation
21. FUTURE GROWTH OPPORTUNITIES
21.1. Chapter Overview
21.2. Technological Advancements to Drive Growth in Vaccine Manufacturing Industry
21.3. Shift to Single-Use Systems and Components for Vaccine Manufacturing
21.4. The Advent of Virus-like Particles (VLPs)
21.5. Growing Investments in Existing Infrastructure
21.6. Evolving Client / Sponsor and CMO / CDMO Relationships
21.7. Business Acquisition and Consolidation Activity
22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats
22.6. Comparison of SWOT Factors
23. CONCLUDING REMARKS
24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Menzo Havenga, Chief Executive Officer and Claire Otjes, Marketing Manager, Batavia Biosciences
24.3. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
24.4. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
24.5. Ingrid Kromann, Ex-Director of Vaccine Development, Statens Serum Institute
24.6. Kevin Daley, Director Pharmaceuticals, Novasep Synthesis
24.7. Thilo Kamphausen, Director Business Development, Richer-Helm BioLogics
24.8. Sebastian Schuck, Head of Business Development, Wacker Biotech
24.9. Oliver Schub, Senior Business Development Manager, ProBioGen
25. APPENDIX 2: TABULATED DATA
26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 5.1 Classification of Vaccines based on their Type
Table 5.2 Toxoid Vaccines: Commonly Reported Adverse Events
Table 5.3 Vaccine Excipients and their Functions
Table 6.1 Vaccine Contract Manufacturers: Information on Year of Establishment, Company Size, Location of Headquarters and Accreditations Received
Table 6.2 Vaccine Contract Manufacturers: Information on Type of Service Offered
Table 6.3 Vaccine Contract Manufacturers: Information on Scale of Operation
Table 6.4 Vaccine Contract Manufacturers: Information on Type of Expression System Used
Table 6.5 Vaccine Contract Manufacturers: Information on Type of Vaccine Manufactured
Table 8.1 Vaccine CMOs: List of Companies Profiled (North America)
Table 8.2 AGC Biologics: Company Overview
Table 8.3 AGC Biologics: Recent Development and Future Outlook
Table 8.4 Bioreliance: Company Overview
Table 8.5 Bioreliance: Recent Developments and Future Outlook
Table 8.6 Catalent: Company Overview
Table 8.7 Catalent: Recent Developments and Future Outlook
Table 8.8 Charles River Laboratories: Company Overview
Table 8.9 Charles River Laboratories: Recent Developments and Future Outlook
Table 8.10 Curia: Company Overview
Table 8.11 Curia: Recent Developments and Future Outlook
Table 8.12 Meridian Life Science: Company Overview
Table 8.13 Meridian Life Science: Recent Developments and Future Outlook
Table 9.1 Vaccine CMOs: List of Companies Profiled (Europe)
Table 9.2 Boehringer Ingelheim BioXcellence: Company Overview
Table 9.3 Boehringer Ingelheim BioXcellence: Recent Developments and Future Outlook
Table 9.4 Eurofins Amatsigroup: Company Overview
Table 9.5 Eurofins Amatsigroup: Recent Developments and Future Outlook
Table 9.6 Eurogentec: Company Overview
Table 9.7 Eurogentec: Recent Developments and Future Outlook
Table 9.8 IDT Biologika: Company Overview
Table 9.9 IDT Biologika: Recent Developments and Future Outlook
Table 9.10 Lonza: Company Overview
Table 9.11 Lonza: Recent Developments and Future Outlook
Table 10.1 Vaccine CMOs: List of Companies Profiled (Asia-Pacific)
Table 10.2 Bharat Biotech: Company Overview
Table 10.3 Bharat Biotech: Recent Developments and Future Outlook
Table 10.4 Biological E: Company Overview
Table 10.5 Biological E: Recent Developments and Future Outlook
Table 10.6 Hong Kong Institute of Biotechnology: Company Overview
Table 10.7 Hong Kong Institute of Biotechnology: Recent Developments and Future Outlook
Table 10.8 Syngene International: Company Overview
Table 10.9 Syngene International: Recent Developments and Future Outlook
Table 10.10 Wockhardt: Company Overview
Table 10.11 Wockhardt: Recent Developments and Future Outlook
Table 10.12 WuXi Biologics: Company Overview
Table 10.13 WuXi Biologics: Recent Developments and Future Outlook
Table 11.1 Vaccine Contract Manufacturers: List of Partnerships and Collaborations, 2020-2024
Table 12.1 Vaccine Contract Manufacturers: List of Recent Expansions, 2020-2024
Table 13.1 Vaccine Contract Manufacturers: List of Mergers and Acquisitions, 2015-2024
Table 14.1 Capacity Analysis: Average Capacity for Mammalian Expression System
Table 14.2 Capacity Analysis: Average Capacity for Microbial Expression System
Table 14.3 Capacity Analysis: Installed Global Capacity
Table 26.1 Vaccine Contract Manufacturers: Distribution by Year of Establishment
Table 26.2 Vaccine Contract Manufacturers: Distribution by Company Size
Table 26.3 Vaccine Contract Manufacturers: Distribution by Location of Headquarters (Region)
Table 26.4 Vaccine Contract Manufacturers: Distribution by Location of Headquarters (Country)
Table 26.5 Vaccine Contract Manufacturers: Distribution by Type of Service Offered
Table 26.6 Vaccine Contract Manufacturers: Distribution by Scale of Operation
Table 26.7 Vaccine Contract Manufacturers: Distribution by Type of Expression System Used
Table 26.8 Vaccine Contract Manufacturers: Distribution by Type of Vaccine Manufactured
Table 26.9 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2020-2024
Table 26.10 Partnerships and Collaborations: Distribution by Type of Partnership
Table 26.11 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 26.12 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 26.13 Most Active Players: Distribution by Number of Partnerships
Table 26.14 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 26.15 Partnerships and Collaborations: Local and International Agreements
Table 26.16 Recent Expansions: Cumulative Year-wise Trend, 2020-2023
Table 26.17 Recent Expansions: Distribution by Type of Expansion
Table 26.18 Recent Expansions: Distribution by Year and Type of Expansion
Table 26.19 Recent Expansions: Distribution by Location of Expanded Facility
Table 26.20 Recent Expansions: Distribution by Purpose of Expansion and Location of Expanded Facility
Table 26.21 Recent Expansions: Distribution by Amount Invested (USD Million)
Table 26.22 Most Active Players: Distribution by Number of Expansions
Table 26.23 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2015-2024
Table 26.24 Mergers and Acquisitions: Distribution by Type of Acquisition
Table 26.25 Mergers and Acquisitions: Local and International Agreements
Table 26.26 Mergers and Acquisitions: Intercontinental and Intracontinental Agreements
Table 26.27 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia-Pacific (2015-2024)
Table 26.28 Most Active Players: Distribution by Number of Deals
Table 26.29 Capacity Analysis: Distribution by Company Size
Table 26.30 Capacity Analysis: Distribution by Type of Expression System Used
Table 26.31 Capacity Analysis: Distribution by Location of Manufacturing Facility
Table 26.32 Global Demand for Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035) (in Million Doses)
Table 26.33 Global Clinical Demand for Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035) (in Million Doses)
Table 26.34 Global Commercial Demand for Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035) (in Million Doses)
Table 26.35 Global Commercial Demand for Vaccines Historical Trends (2020-2023) and Forecasted Estimates (2024-2035): Distribution by Geographical Region (in Million Doses)
Table 26.36 Global Clinical Demand for COVID-19 Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035)
Table 26.37 Global Commercial Demand for COVID-19 Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035)
Table 26.38 Global Vaccine Contract Manufacturing Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.39 Global Vaccine Contract Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Table 26.40 Global Vaccine Contract Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Table 26.41 Vaccine Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, 2024 and 2035
Table 26.42 Vaccine Contract Manufacturing Market for Mammalian Expression System: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.43 Vaccine Contract Manufacturing Market for Microbial Expression System: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.44 Vaccine Contract Manufacturing Market for Other Expression System: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.45 Vaccine Contract Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
Table 26.46 Vaccine Contract Manufacturing Market for Small Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Table 26.47 Vaccine Contract Manufacturing Market for Mid-sized Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Table 26.48 Vaccine Contract Manufacturing Market for Large and Very Large Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Table 26.49 Vaccine Contract Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
Table 26.50 Vaccine Contract Manufacturing Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.51 Vaccine Contract Manufacturing Market in US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.52 Vaccine Contract Manufacturing Market in Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.53 Vaccine Contract Manufacturing Market in Rest of North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.54 Vaccine Contract Manufacturing Market for Mammalian Expression System in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.55 Vaccine Contract Manufacturing Market for Microbial Expression System in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.56 Vaccine Contract Manufacturing Market for Other Expression System t in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.57 Vaccine Contract Manufacturing Market for Small Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.58 Vaccine Contract Manufacturing Market for Mid-sized Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.59 Vaccine Contract Manufacturing Market for Large / Very Large Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.60 Vaccine Contract Manufacturing Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.61 Vaccine Contract Manufacturing Market in Germany: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.62 Vaccine Contract Manufacturing Market in UK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.63 Vaccine Contract Manufacturing Market in France: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.64 Vaccine Contract Manufacturing Market in Italy: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.65 Vaccine Contract Manufacturing Market in Spain: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.66 Vaccine Contract Manufacturing Market in Rest of Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.67 Vaccine Contract Manufacturing Market for Mammalian Expression System in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.68 Vaccine Contract Manufacturing Market for Microbial Expression System in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.69 Vaccine Contract Manufacturing Market for Other Expression System in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.70 Vaccine Contract Manufacturing Market for Small Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.71 Vaccine Contract Manufacturing Market for Mid-sized Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.72 Vaccine Contract Manufacturing Market for Large / Very Large Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.73 Vaccine Contract Manufacturing Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.74 Vaccine Contract Manufacturing Market in China: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.75 Vaccine Contract Manufacturing Market in India: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.76 Vaccine Contract Manufacturing Market in Japan: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.77 Vaccine Contract Manufacturing Market in Rest of Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.78 Vaccine Contract Manufacturing Market for Mammalian Expression System in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.79 Vaccine Contract Manufacturing Market for Microbial Expression System in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.80 Vaccine Contract Manufacturing Market for Other Expression System in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.81 Vaccine Contract Manufacturing Market for Small Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.82 Vaccine Contract Manufacturing Market for Mid-sized Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.83 Vaccine Contract Manufacturing Market for Large / Very Large Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.84 Vaccine Contract Manufacturing Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 26.85 Vaccine Contract Manufacturing Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)